One visit, two shots: study tests combining RSV and shingles vaccines

NCT ID NCT06890416

Completed ⭐️ VACCINE ⭐️ Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 26 times

Summary

This study tested whether giving the RSV vaccine (Abrysvo) and the shingles vaccine (Shingrix) at the same doctor's visit is safe and works as well as giving them separately. About 526 adults aged 50 and older took part. Researchers measured immune responses and tracked side effects like pain, fatigue, and fever for up to 4 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AMR Clinical

Mobile, Alabama, 36608, United States
Alliance for Multispecialty Research, LLC

Doral, Florida, 33172, United States
Central Research Associates

Birmingham, Alabama, 35205, United States
Centricity Research Columbus Georgia Multispecialty

Columbus, Georgia, 31904, United States
Centricity Research Columbus Ohio Multispecialty

Columbus, Ohio, 43213, United States
Clinical Neuroscience Solutions Inc.

Memphis, Tennessee, 38119, United States
Clinical Research Atlanta

Stockbridge, Georgia, 30281, United States
Clinical Research Professionals

Chesterfield, Missouri, 63005, United States
Clinical Research Puerto Rico

San Juan, 00909, Puerto Rico
DM Clinical Research - Bellaire

Houston, Texas, 77081, United States
DM Clinical Research - Philadelphia

Philadelphia, Pennsylvania, 19107, United States
DM Clinical Research - Sugar Land

Sugar Land, Texas, 77478, United States
De La Cruz Research Center, LLC

Miami, Florida, 33184, United States
DelRicht Research

New Orleans, Louisiana, 70115, United States
Diablo Clinical Research, Inc.

Walnut Creek, California, 94598, United States
IMA Clinical Research San Antonio

San Antonio, Texas, 78229, United States
IMA Clinical Research Warren

Warren Township, New Jersey, 07059, United States
Jadestone Clinical Research

Silver Spring, Maryland, 20904, United States
Kaiser Permanente

Los Angeles, California, 90027, United States
Medical Affiliated Research Center

Huntsville, Alabama, 35801, United States
NYU Langone Health

New York, New York, 10016, United States
Oakland Medical Research

Troy, Michigan, 48085, United States
Optimal Research

Peoria, Illinois, 61614, United States
Proactive Clinical Research,LLC

Fort Lauderdale, Florida, 33308, United States
SMS Clinical Research

Mesquite, Texas, 75149, United States
Synexus Clinical Research US, Inc.

Chicago, Illinois, 60602, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RSV prefusion F subunit vaccine (Abrysvo) and herpes zoster subunit vaccine (Shingrix)

What this could lead to

If successful, this could show that getting both vaccines at the same visit is safe and effective, simplifying protection against RSV and shingles for older adults.

What could go wrong

This is a completed Phase 3 study, but results are not yet published. Combining vaccines may cause more side effects or slightly lower immune responses than giving them separately.

Conditions

The condition(s) this trial relates to.

herpes zoster prevention target respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS (RSV) RESPIRATORY SYNCYTIAL VIRUS (RSV)